Future clinical prospects of C-peptide testing in the early diagnosis of gestational diabetes
©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved..
Gestational diabetes is typically diagnosed in the late second or third trimester of pregnancy. It is one of the most common metabolic disorders among expectant mothers, with potential serious short- and long-term complications for both maternal and offspring health. C-peptide is secreted from pancreatic beta-cells into circulation in equimolar amounts with insulin. It is a useful biomarker to estimate the beta-cell function because it undergoes negligible hepatic clearance and consequently it has a longer half-life compared to insulin. Pregnancy induces increased insulin resistance due to physiological changes in hormonal and metabolic homeostasis. Inadequate compensation by islet beta-cells results in hyperglycemia. The standard oral glucose tolerance test at 24-28 wk of gestation sets the diagnosis. Accumulated evidence from prospective studies indicates a link between early pregnancy C-peptide levels and the risk of subsequent gestational diabetes. Elevated C-peptide levels and surrogate glycemic indices at the beginning of pregnancy could prompt appropriate strategies for secondary prevention.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:14 |
|---|---|
| Enthalten in: |
World journal of experimental medicine - 14(2024), 1 vom: 20. März, Seite 89320 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Milionis, Charalampos [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
C-peptide |
|---|
| Anmerkungen: |
Date Revised 10.04.2024 published: Electronic-eCollection Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.5493/wjem.v14.i1.89320 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM370796543 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM370796543 | ||
| 003 | DE-627 | ||
| 005 | 20240410233021.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240409s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.5493/wjem.v14.i1.89320 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1371.xml |
| 035 | |a (DE-627)NLM370796543 | ||
| 035 | |a (NLM)38590302 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Milionis, Charalampos |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Future clinical prospects of C-peptide testing in the early diagnosis of gestational diabetes |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 10.04.2024 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a ©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved. | ||
| 520 | |a Gestational diabetes is typically diagnosed in the late second or third trimester of pregnancy. It is one of the most common metabolic disorders among expectant mothers, with potential serious short- and long-term complications for both maternal and offspring health. C-peptide is secreted from pancreatic beta-cells into circulation in equimolar amounts with insulin. It is a useful biomarker to estimate the beta-cell function because it undergoes negligible hepatic clearance and consequently it has a longer half-life compared to insulin. Pregnancy induces increased insulin resistance due to physiological changes in hormonal and metabolic homeostasis. Inadequate compensation by islet beta-cells results in hyperglycemia. The standard oral glucose tolerance test at 24-28 wk of gestation sets the diagnosis. Accumulated evidence from prospective studies indicates a link between early pregnancy C-peptide levels and the risk of subsequent gestational diabetes. Elevated C-peptide levels and surrogate glycemic indices at the beginning of pregnancy could prompt appropriate strategies for secondary prevention | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a C-peptide | |
| 650 | 4 | |a Clinical laboratory techniques | |
| 650 | 4 | |a Gestational diabetes | |
| 650 | 4 | |a Pregnancy | |
| 650 | 4 | |a Secondary prevention | |
| 700 | 1 | |a Ilias, Ioannis |e verfasserin |4 aut | |
| 700 | 1 | |a Lekkou, Anastasia |e verfasserin |4 aut | |
| 700 | 1 | |a Venaki, Evangelia |e verfasserin |4 aut | |
| 700 | 1 | |a Koukkou, Eftychia |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t World journal of experimental medicine |d 2011 |g 14(2024), 1 vom: 20. März, Seite 89320 |w (DE-627)NLM235380636 |x 2220-315X |7 nnns |
| 773 | 1 | 8 | |g volume:14 |g year:2024 |g number:1 |g day:20 |g month:03 |g pages:89320 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.5493/wjem.v14.i1.89320 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 14 |j 2024 |e 1 |b 20 |c 03 |h 89320 | ||